Non-alcoholic fatty liver disease (NAFLD) is a potentially serious liver disease that affects
approximately one-quarter of the global adult population, causing a substantial burden of ill …

Objective To provide evidence-based recommendations regarding the diagnosis and
management of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis …

Non-alcoholic fatty liver disease (NAFLD) is now the leading cause of chronic liver disease
globally. Despite the increased demand placed on health-care systems, little attention has …

Nonalcoholic fatty liver disease (NAFLD) is a major public health problem worldwide and the
most common chronic liver disease. NAFLD currently affects approximately one in every four …

Patients with chronic liver disease are often diagnosed during an index presentation to
hospital with decompensated cirrhosis or liver-related events, and these presentations are …

Background Non-alcoholic fatty liver disease (NAFLD) is highly prevalent worldwide.
Identifying high-risk patients is critical to best utilize limited health care resources. We …

Non-alcoholic fatty liver disease (NAFLD) is the most prevalent liver disease and is the
hepatic expression of metabolic syndrome. The development of non-invasive methods for …

Addressing primary care's low confidence in detecting and managing chronic liver disease
is becoming increasingly important owing to the escalating prevalence of its common …

Non-alcoholic fatty liver disease (NAFLD) affects approximately 8 million Canadians. NAFLD
refers to a disease spectrum ranging from bland steatosis to non-alcoholic steatohepatitis …

More than one-third of the adult world population has steatotic liver disease (SLD), with a
few percent of individuals developing cirrhosis after decades of silent liver fibrosis …